Physician profile
John Rickard
NPI 1083880876
$108,916.70
in general payments reported to CMS, 2019-2025
19 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $12K · 2021: $26K · 2022: $5,624 · 2023: $4,654 · 2024: $7,849 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,875 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,025 · Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,875.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,025.00 |
| Food and Beverage | $1,477.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $62,886.96 | 2019-2024 | Gallant, Ensite Precision |
| Medtronic Vascular, INC. | $20,002.24 | 2019-2020 | |
| Boston Scientific Corporation | $16,713.92 | 2019-2025 | General - Therapies, Vigilant X4 Crt-D |
| Medtronic, INC. | $7,786.31 | 2021-2024 | Micra, Arctic Front Advance |
| Biosense Webster, INC. | $667.78 | 2019-2024 | Carto 3 |
| Philips North America LLC | $159.20 | 2023-2024 | (Am5) Lead Management |
| Impulse Dynamics (USA) INC. | $151.67 | 2022-2024 | Optimizer |
| Amgen INC. | $127.68 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $116.11 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $62.18 | 2019-2024 | Eliquis |
| Novo Nordisk INC | $54.13 | 2022-2023 | Ozempic, Rybelsus |
| Azurity Pharmaceuticals, INC. | $36.06 | 2024 | Edarbyclor |
| Pfizer INC. | $34.16 | 2019-2021 | |
| Ekos Corporation | $23.99 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.16 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $19.64 | 2020 | |
| United Therapeutics Corporation | $18.73 | 2023 | Orenitram |
| Astrazeneca Pharmaceuticals Lp | $16.79 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rickard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.